Times are tough, but activist investors are still finding some diamonds among the rough.
have made five nominations to the board of directors of
( AMLN) in attempts to possibly sell the company to a larger biotechnology firm.
As of their latest filings, Carl Icahn owns approximately 8.3% of Amylin, and Eastbourne Capital owns approximately 12.5%.
San Diego-based Amylin Pharmaceuticals is the maker of the diabetes drug Byetta, with a joint 50-50 partnership with
, thus making Lilly the most likely candidate to buy Amylin.
To read more about this and other activist situations,
Stockpickr is a wholly owned subsidiary of TheStreet.com.